In addition to being a diagnostic utility, detection of MDM2 amplification and CHOP rearrangement impact liposarcoma treatments that use selective MDM2 inhibitors and blockers of trans-activating ability of FUS-CHOP fusion protein (31). The gene discussed is MDM2; the disease is liposarcoma.